Krystal’s mission is to develop and deliver genetic medicines to patients using redosable gene therapies for the treatment of severe, life‑threatening or rare diseases that have limited or no approved therapies.

Using a clinically-proven platform, Krystal’s approach is based on a modified and engineered HSV‑1 vector that is replication‑defective and non‑integrating.

With two GMP facilities, find out about what goes into the manufacturing of gene therapies and making transformative medicines.

Krystal is pursuing some of the world’s most debilitating genetic diseases for patients who have limited or inadequate treatment options.